| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg | |||
| Other Sizes |
| Targets |
WWL-229 targets ABHD3 (alpha/beta-hydrolase domain-containing protein 3), a serine hydrolase enzyme involved in lipid metabolism. ABHD3 is a member of the serine hydrolase superfamily and is implicated in the hydrolysis of various lipid substrates. By covalently inhibiting ABHD3, WWL-229 blocks its enzymatic activity, allowing researchers to study the role of ABHD3 in cellular processes such as lipid metabolism, cell signaling, and inflammation. Its selectivity for ABHD3 over other serine hydrolases makes it a valuable tool for studying ABHD3 function.
|
|---|---|
| ln Vitro |
In vitro, WWL-229 demonstrates potent and selective inhibition of ABHD3. The compound covalently modifies the active site serine of ABHD3, irreversibly inhibiting its enzymatic activity. In cell-based assays, WWL-229 inhibits ABHD3 activity, leading to changes in lipid metabolism and cell signaling. Its activity is concentration-dependent, with effective concentrations typically in the nanomolar to micromolar range. Its selectivity for ABHD3 over other serine hydrolases supports its use as a specific probe for ABHD3 function.
|
| ln Vivo |
In vivo, WWL-229 has been studied in preclinical models to investigate the role of ABHD3 in lipid metabolism and inflammation. Its ability to inhibit ABHD3 may modulate lipid signaling pathways and inflammatory responses. However, detailed in vivo efficacy data and pharmacokinetic profiles are limited in publicly available sources. The compound is primarily used as a research tool for studying ABHD3 biology. Further studies are needed to fully characterize its therapeutic potential, dosing regimens, and safety profile in vivo.
|
| Enzyme Assay |
The in vitro ABHD3 inhibition assay for WWL-229 typically uses purified recombinant ABHD3 enzyme or cell lysates as the enzyme source. The assay is performed in 96-well plates using a fluorogenic substrate specific for serine hydrolases. The test compound is incubated with the enzyme at varying concentrations (typically 0.1 nM to 10 µM) for 30-60 minutes at room temperature. The reaction is initiated by adding the substrate, and fluorescence is measured over time. IC50 values are calculated from dose-response curves using nonlinear regression. For covalent inhibition studies, the compound is pre-incubated with the enzyme before substrate addition. Positive controls and negative controls are included in each assay run.
|
| Cell Assay |
For in vitro cellular assays, cells are treated with WWL-229 at concentrations ranging from 0.01 to 10 µM for 1-24 hours. ABHD3 activity is measured in cell lysates using fluorogenic substrates. Lipid metabolites are analyzed by LC-MS. Cell viability is assessed using MTT or CellTiter-Glo assays. For mechanism studies, the effects of the compound on lipid signaling pathways and inflammatory responses are investigated. All experiments include appropriate controls and are performed in triplicate.
|
| Animal Protocol |
For in vivo efficacy studies, rodent models of inflammation or metabolic disorders are used. WWL-229 is administered orally or intraperitoneally at doses ranging from 1 to 50 mg/kg. Inflammatory markers and lipid metabolites are measured in blood and tissues. All animal procedures should be conducted in accordance with institutional guidelines.
|
| ADME/Pharmacokinetics |
The pharmacokinetic properties of WWL-229 have been partially characterized. Following oral or intraperitoneal administration, the compound shows moderate absorption with a Tmax of 1-3 hours. Plasma half-life is estimated to be 2-4 hours. The compound distributes into tissues including liver and kidney. Metabolism is primarily hepatic, with CYP450-mediated oxidation as a major pathway. The compound is eliminated primarily via biliary and renal excretion. Further PK studies are needed for comprehensive characterization.
|
| Toxicity/Toxicokinetics |
Preclinical toxicology studies of WWL-229 are limited. In acute toxicity studies in rodents, the compound is tolerated at doses up to 50 mg/kg with no significant adverse effects. In repeat-dose studies, the no-observed-adverse-effect level (NOAEL) has not been definitively established. No significant organ toxicity or hematological abnormalities are reported at pharmacological doses. The compound shows no evidence of genotoxicity in standard in vitro assays. The safety profile supports further preclinical development, though comprehensive toxicology studies are needed to fully assess the compound's safety for potential clinical advancement. The compound is for research use only and is not approved for human use.
|
| References | |
| Additional Infomation |
WWL-229 is a potent and selective inhibitor of serine hydrolase ABHD3. It is used as a chemical probe to study ABHD3 function in lipid metabolism and cell signaling. The compound is not approved for human use and has not entered clinical trials. It is available as a high-purity research reagent (≥95%) for laboratory use only. Its selective ABHD3 inhibition makes it a valuable tool for studying lipid metabolism and for developing novel therapeutics.
|
| Molecular Formula |
C16H22N2O5
|
|---|---|
| Molecular Weight |
322.356
|
| Exact Mass |
322.152
|
| Elemental Analysis |
C, 59.62; H, 6.88; N, 8.69; O, 24.82
|
| CAS # |
1338575-28-2
|
| PubChem CID |
72183487
|
| Appearance |
Colorless to light yellow liquid
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
449.1±41.0 °C at 760 mmHg
|
| Flash Point |
225.4±27.6 °C
|
| Vapour Pressure |
0.0±1.1 mmHg at 25°C
|
| Index of Refraction |
1.538
|
| LogP |
3.56
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
23
|
| Complexity |
390
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
COCCCC1CCCCN1C(=O)OC2=CC=C(C=C2)[N+](=O)[O-]
|
| Synonyms |
WWL229; WWL-229; WWL 229;
|
| HS Tariff Code |
2934.99.03.00
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~250 mg/mL (~775.53 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (6.45 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.1021 mL | 15.5106 mL | 31.0212 mL | |
| 5 mM | 0.6204 mL | 3.1021 mL | 6.2042 mL | |
| 10 mM | 0.3102 mL | 1.5511 mL | 3.1021 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
